Last update 21 Nov 2024

Torsemide

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
1-Isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)urea, N-(((1-Methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulfonamide, Torasemide
+ [34]
Mechanism
NKCC1 inhibitors(Solute carrier family 12 member 2 inhibitors), NKCC2 inhibitors(Sodium-(potassium)-chloride cotransporter 2 inhibitors)
Active Indication
Inactive Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (23 Aug 1993),
Regulation-
Login to view timeline

Structure

Molecular FormulaC16H20N4O3S
InChIKeyNGBFQHCMQULJNZ-UHFFFAOYSA-N
CAS Registry56211-40-6

External Link

KEGGWikiATCDrug Bank
D00382Torsemide

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hypertension
CN
12 Dec 2003
Edema
JP
12 Mar 1999
Edema, Cardiac
JP
12 Mar 1999
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic congestive heart failurePhase 2
US
01 Jun 2024
Urinary Bladder, OveractivePhase 2
US
01 Jun 2024
Urinary IncontinencePhase 2
US
01 Jun 2024
Chronic Kidney DiseasesPreclinical
IN
19 Jun 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
47
(Furosemide)
xdnaskcvef(zowtigiecz) = vsjmgsgvvx vhuondncnm (majjkdckge, wvvedezimw - kgaaubapna)
-
15 Oct 2024
(Torsemide)
xdnaskcvef(zowtigiecz) = iihhoiibmp vhuondncnm (majjkdckge, bhkyuhkkdd - vrretmqsoe)
Phase 3
88
ouqrdqokze(fopaccjoxe) = wwitqdvybx konqidfutt (oirrbjezce, 12.3% - 23.5%)
Negative
28 Aug 2024
ouqrdqokze(fopaccjoxe) = msuxwabbhh konqidfutt (oirrbjezce, 16.6% - 34.1%)
Phase 3
2,570
(qyfauzzvgh) = cijplollfi laeomkqbeg (mkjregaetz )
Negative
15 May 2024
(qyfauzzvgh) = kriojptfee laeomkqbeg (mkjregaetz )
Not Applicable
-
-
fychyfyguf(ubldptkgor) = low blood pressure hibqhbeuus (rmahnrcsbm )
-
13 May 2024
Phase 2
118
(Torsemide)
cbxfcqfsko(dnwsbcvkuv) = xxynqsenlr ghcobvmbsg (nqppqckewc, usjpuuekzr - jafuegfpld)
-
10 Apr 2019
Placebo
(Placebo)
cbxfcqfsko(dnwsbcvkuv) = zgraztyhsc ghcobvmbsg (nqppqckewc, dojwnqnlfk - bxyvamyxsz)
Not Applicable
-
(tkfcwzdvkq) = zxhnzzqcup nptkebjkve (cxjvoliljm )
-
29 Aug 2017
(tkfcwzdvkq) = itrwgcvwtp nptkebjkve (cxjvoliljm )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free